Holly Keir

Ms. Holly Keir


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MAMicheál Mac Aogáin
Micheál Mac Aogáin
JNJayanth Kumar Narayana
Jayanth Kumar Narayana
PTPei Yee Tiew
Pei Yee Tiew
NANur A’tikah Binte Mohamed Ali
Nur A’tikah Binte Mohamed Ali
VYValerie Fei Lee Yong
Valerie Fei Lee Yong
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall

23 February 2022 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
HKHolly Keir
Holly Keir
JCJames D. Chalmers
James D. Chalmers
Neutrophilic inflammation has a key role in the pathophysiology of multiple chronic lung diseases. The formation of neutrophil extracellular traps (NETs) has emerged as a key mechanism of disease in neutrophilic lung diseases including asthma, COPD, cystic fibrosis and, most recently, bronchiectasis. NETs are large, web-like structures composed of DNA and anti-microbial proteins that are able to bind pathogens, prevent microbial dissemination and degrade bacterial virulence factors. The release of excess concentrations of proteases, antimicrobial proteins, DNA and histones, however, also leads to tissue damage, impaired mucociliary clearance, impaired bacterial killing and increased inflammation. A number of studies have linked airway NET formation with greater disease severity, increased exacerbations and overall worse disease outcomes across the spectrum of airway diseases. Treating neutrophilic inflammation has been challenging in chronic lung disease because of the delicate balance between reducing inflammation and increasing the risk of infections through immunosuppression. Novel approaches to suppressing NET formation or the associated inflammation are in development and represent an important therapeutic target. This review will discuss the relationship between NETs and the pathophysiology of cystic fibrosis, asthma, COPD and bronchiectasis, and explore the current and future development of NET-targeting therapies.

24 September 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
HKHolly Keir
Holly Keir
MCMarco Contoli
Marco Contoli
JCJames D. Chalmers
James D. Chalmers
The Global Initiative for Chronic Obstructive Lung Disease 2021 Report recommends inhaled corticosteroid (ICS)-containing regimens as part of pharmacological treatment in patients with chronic obstructive lung disease (COPD) and frequent exacerbations, particularly with eosinophilic inflammation. However, real-world studies reveal overprescription of ICS in COPD, irrespective of disease presentation and inflammatory endotype, leading to increased risk of side effects, mainly respiratory infections. The optimal use of ICS in COPD therefore remains an area of intensive research, and additional biomarkers of benefit and risk are needed. Although the interplay between inflammation and infection in COPD is widely acknowledged, the role of the microbiome in shaping lower airway inflammation has only recently been explored. Next-generation sequencing has revealed that COPD disease progression and exacerbation frequency are associated with changes in the composition of the lung microbiome, and that the immunosuppressive effects of ICS can contribute to potentially deleterious airway microbiota changes by increasing bacterial load and the abundance of potentially pathogenic taxa such as Streptococcus and Haemophilus. Here, we explore the relationship between microbiome, inflammation, ICS use and disease phenotype. This relationship may inform the benefit:risk assessment of ICS use in patients with COPD and lead to more personalised pharmacological management.

10 May 2022 in Breathe
Verified
Journal Article
Open access
PDF file
CNCláudio Nunes-Silva
Cláudio Nunes-Silva
AVAna Teresa Vilares
Ana Teresa Vilares
VSValentijn Schweitzer
Valentijn Schweitzer
SCSusana Castanhinha
Susana Castanhinha
AMAntónio Martins
António Martins
MTMargarida Tavares
Margarida Tavares
Implemented control measures brought about by the coronavirus disease 2019 (COVID-19) pandemic have changed the prevalence of other respiratory viruses, often relegating them to a secondary plan. However, it must not be forgotten that a diverse group of viruses, including other human coronaviruses, rhinoviruses, respiratory syncytial virus, human metapneumoviruses, parainfluenza and influenza, continue to be responsible for a large burden of disease. In fact, they are among the most common causes of acute upper and lower respiratory tract infections globally. Viral respiratory infections can be categorised in several ways, including by clinical syndrome or aetiological agent. We describe their clinical spectrum. Distinctive imaging features, advances in microbiological diagnosis and treatment of severe forms are also discussed.Educational aims: To summarise the knowledge on the spectrum of disease that respiratory viral infections can cause and recognise how often they overlap. To learn the most common causes of respiratory viral infections and acknowledge other less frequent agents that may target certain key populations (e.g.immunocompromised patients). To improve awareness of the recent advances in diagnostic methods, including molecular assays and helpful features in imaging techniques. To identify supportive care strategies pivotal in the management of severe respiratory viral infections.

14 December 2023 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MLMerete B. Long
Merete B. Long
AHAndrew J.M. Howden
Andrew J.M. Howden
HKHolly Keir
Holly Keir
CRChristina M. Rollings
Christina M. Rollings
YGYan Hui Giam
Yan Hui Giam
ABAlejandro J. Brenes
Alejandro J. Brenes
Background: Neutrophils are important in the pathophysiology of coronavirus disease 2019 (COVID-19), but the molecular changes contributing to altered neutrophil phenotypes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not fully understood. We used quantitative mass spectrometry-based proteomics to explore neutrophil phenotypes immediately following acute SARS-CoV-2 infection and during recovery.Methods: Prospective observational study of hospitalised patients with PCR-confirmed SARS-CoV-2 infection (May to December 2020). Patients were enrolled within 96 h of admission, with longitudinal sampling up to 29 days. Control groups comprised non-COVID-19 acute lower respiratory tract infection (LRTI) and age-matched noninfected controls. Neutrophils were isolated from peripheral blood and analysed using mass spectrometry. COVID-19 severity and recovery were defined using the World Health Organization ordinal scale.Results: Neutrophil proteomes from 84 COVID-19 patients were compared to those from 91 LRTI and 42 control participants. 5800 neutrophil proteins were identified, with >1700 proteins significantly changed in neutrophils from COVID-19 patients compared to noninfected controls. Neutrophils from COVID-19 patients initially all demonstrated a strong interferon signature, but this signature rapidly declined in patients with severe disease. Severe disease was associated with increased abundance of proteins involved in metabolism, immunosuppression and pattern recognition, while delayed recovery from COVID-19 was associated with decreased granule components and reduced abundance of metabolic proteins, chemokine and leukotriene receptors, integrins and inhibitory receptors.Conclusions: SARS-CoV-2 infection results in the sustained presence of circulating neutrophils with distinct proteomes suggesting altered metabolic and immunosuppressive profiles and altered capacities to respond to migratory signals and cues from other immune cells, pathogens or cytokines.

13 April 2022 in Respirology
Verified
Journal Article
Closed access
HKHolly Keir
Holly Keir
JCJames D. Chalmers
James D. Chalmers